Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Journal of Clinical Rheumatology 2004-Oct

Fracture complicating the bone marrow edema syndrome.

Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Saite tiek saglabāta starpliktuvē
Sherry A Guardiano
James Katz
Arnold M Schwartz
Kathleen Brindle
Rudolfo Curiel

Atslēgvārdi

Abstrakts

Bone marrow edema syndrome (BMES), also known as transient regional osteoporosis, is a rare and poorly understood disease process. We present a case of an elderly patient with the BMES who had a relapsing and remitting course complicated by a hip fracture which presented the unique and a previously unreported opportunity to examine the bony architecture pathologically. The patient responded well to calcitonin and bisphosphonate therapy after surgical repair of his fracture.This case highlights an underappreciated potential complication of BMES. Though not previously reported in the literature, BMES may be associated with active osteoporotic changes, with an infrequent risk of fracture that may be amenable to potential therapeutic interventions. Pathologically, BMES may represent a spectrum of disease consisting of an osteoclast-rich phase (transient regional osteoporosis phase) predisposing to fracture in addition to the more indolent osteoclast-poor phase with bone marrow edema more commonly associated with the disease. We hypothesize that it is the osteoclastic-rich phase which may benefit from early introduction of weight bearing activities, calcitonin, bisphosphonates, or parathyroid hormone. For example, bisphosphonates reduce bone resorption directly. Indirectly, bisphosphonates may also increase osteoblast differentiation and number and thus improve bone quality, an added benefit in the treatment of bone involved in the BMES, whether in the osteoclast-rich or osteoclast-poor phase.Further study should evaluate this osteoclastic-rich phase, which may be a transient pathologic phenomenon and which has not been described previously. Transient regional osteoporosis, therefore, may represent one point in the spectrum of the BMES. Hence, we would argue that BMES is a more accurate name for the full spectrum of this disease entity.

Pievienojieties mūsu
facebook lapai

Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne

  • Darbojas 55 valodās
  • Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
  • Garšaugu atpazīšana pēc attēla
  • Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
  • Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
  • Meklēt ārstniecības augus pēc to iedarbības
  • Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem

Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem

Google Play badgeApp Store badge